
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is a leader in various therapeutic areas, with its key products including Verzenio, Jaypirca, Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, Humulin, Taltz, and Olumiant. The company's performance in the second quarter of 2026 was above expectations, with revenue of $20.7 billion (beating consensus of $20.5 billion), driven by strong sales of its cancer, cardiometabolic, and immunology products. With upcoming catalysts, such as the FDA approval and launch of Foundayo in the US and potential UK launch, the company's revenue is expected to continue to grow. Furthermore, Eli Lilly's focus on sustainability and its promising pipeline, including eloralintide for obesity and other genetic GLP-1 resistant patients, generate positive expectations for long-term growth and differentiation in the pharmaceutical industry.
Bears say
Eli Lilly is facing several challenges, including slow uptake of its new products like Foundayo and pricing pressures on its key product, Tirzepatide. The company may also face difficulties in meeting enrollment targets for clinical trials, particularly in underrepresented populations. Additionally, competition from novel therapies and concerns about high multiples could put pressure on the company's stock. To address these challenges, Eli Lilly should articulate specific enrollment targets and community partnership strategies for pivotal trials, establish differentiated pricing for lower-income markets, and provide more clarity on allocation principles and access commitments.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares